cool
Gilead's Remdesivir Shows Consistent Efficacy In Patients With Comorbidities With Higher Risk for Severe COVID-19
Gilead Sciences Inc announced full results from a Phase 3 study of a three-day course of Veklury (re
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
4
举报
登录后可参与评论
![empty](https://c1.itigergrowtha.com/community/assets/media/empty-default.06ba11e0.png)
暂无评论